Aligos Therapeutics, Inc.
ALGS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.01 | -0.00 | -0.00 |
| FCF Yield | -24.15% | -20.92% | -30.20% | -7.36% |
| EV / EBITDA | -2.32 | -4.07 | -0.19 | -11.14 |
| Quality | ||||
| ROIC | -30.99% | -15.92% | -14.21% | -36.07% |
| Gross Margin | 0.00% | 73.16% | 100.00% | -6.68% |
| Cash Conversion Ratio | 0.77 | 0.98 | -0.49 | 0.22 |
| Growth | ||||
| Revenue 3-Year CAGR | -45.54% | -43.12% | -38.50% | -34.29% |
| Free Cash Flow Growth | -57.16% | 25.48% | -13.68% | 8.43% |
| Safety | ||||
| Net Debt / EBITDA | 1.27 | 0.77 | 3.52 | 1.44 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -1,368.07 | 0.00 | 0.00 |